Medical Evidence
Anti-Inflammatory Activity of Chondroitin
Sulfate Francesca Ronca, Lina Palmieri, Patrizia
Panicucci And Giovanni Ronca Department of Human and Environmental
Sciences, University of Pisa, Italy
Summary: The pharmacokinetics
of chondroitin sulfate (CS, Condrosulf®, IBSA, Lugano, Switzerland)
were investigated in rats and in healthy volunteers using CS tritiated
at the reducing end and CS labeled with 131I or 99mTc respectively.
A rapid absorption of orally administered CS is observed in rats
and in humans when the drug is dissolved in water. Lower and delayed
absorption is observed when CS is administered in gastroresistant
capsules. The absolute bio-availability is 15 and 12% for rats
and human respectively. The CS shows a tropism for cartilagineous
tissues in rats and for knee tissues in humans as demonstrated
by scintigraphic analysis with 99mTc-CS. Monomers, oligo and polysaccharides
produced by enzymatic hydrolysis of CS appear in the blood and
tissues together with native CS. The effects of partially depolymerized
(m.m. 3 to 15 kD) and desulfated fractions on human leukocytes
were investigated. CS and its fractions inhibit the directional
chemotaxis induced by zymosan-activated serum, are able to decrease
the phagocytosis and the release of lysozyme induced by zymosan
and to protect the plasma membrane from oxygen reactive species.
In rats the oral administration of CS significantly decreases
granuloma formation due to sponge implants and cell migration
and lysosomal enzyme release in carrageenan pleurisy. Compared
with nonsteroidal anti-inflammatory drugs (indomethacin, ibuprofen),
CS appears to be more effective on cellular events of inflammation
than on edema formation. It is noteworthy that CS is devoid of
dangerous effects on the stomach, platelets and kidneys. In synovial
fluid of patients requiring joint aspiration, treated orally for
10 days with CS (800 mg/day) the hyaluronate concentration and
the intrinsic viscosity significantly increased, while collagenolytic
activity, phospholipase A2 and N-acetylglucosaminidase (NAG) decreased.
Results: These results
give an insight into the mechanism of the anti-inflammatory and
chondroprotective actions demonstrated by this drug in a number
of clinical trials in patients with osteoarthritis.
Source: Osteoarthritis and
Cartilage (1998) 6, (Supplement A), 14-21 Osteoarthritis Research
Society
Dr. Theo's Comments: This
study helps show the mechanism of action of chondroitin sulfate.
The study also proves that chondroitin sulfate is indeed absorbed
in humans when taken by mouth. This is not surprising, since so
many clinical trials have proven the oral form of chondroitin
works well in treating osteoarthritis.